Download PDF AVEO’s Human Response Platform(TM) Enables Discovery of Biomarkers to Predict Patient Response CAMBRIDGE, Mass., Jun 16, 2010 (BUSINESS WIRE) –AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the issuance of U.S. Patent Nos. 7,615,353, which issued in November 2009, and 7,736,861, which issued
Category: Press Release
AVEO Pharmaceuticals’ Tivozanib Demonstrates Progression-Free Survival of 14.8 Months in Subgroup of Patients with Advanced Kidney Cancer; Extended Duration of Treatment Continues to Highlight Favorable Tolerability Profile
Download PDF Additional Phase 2 Data Presented at ASCO; Phase 3 TIVO-1 Trial Underway to Evaluate Tivozanib’s Efficacy and Safety Profile CAMBRIDGE, Mass. & CHICAGO, Jun 07, 2010 (BUSINESS WIRE) –AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced data from a subgroup analysis of a
AVEO Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating SCH 900105 (AV-299) in Non-Small Cell Lung Cancer
Download PDF Results of Phase 1 Trial Presented at ASCO Annual Meeting CAMBRIDGE, Mass., Jun 05, 2010 (BUSINESS WIRE) –AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated a Phase 2 clinical trial evaluating SCH 900105 (also referred to as AV-299) for
AVEO Pharmaceuticals to Present at the Bank of America Merrill Lynch 2010 Smid Cap Conference
Download PDF CAMBRIDGE, Mass., Jun 02, 2010 (BUSINESS WIRE) –AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Bank of America Merrill Lynch 2010 Smid Cap Conference on Wednesday, June 9, 2010 at
AVEO Pharmaceuticals to Present at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting
Download PDF Additional Analyses from Phase 2 Trial of Tivozanib and Phase 1 AV-299 Data to be Presented CAMBRIDGE, Mass., May 20, 2010 (BUSINESS WIRE) –AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that data from the company’s tivozanib and AV-299 (SCH 900105) programs will be
AVEO Reports First Quarter 2010 Financial Results
Download PDF Significant Progress in Development of Lead Product Candidate Tivozanib; 2010 Financial Guidance Provided CAMBRIDGE, Mass., Apr 29, 2010 (BUSINESS WIRE) –AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced financial results for the quarter ended March 31, 2010, provided an update on progress towards
AVEO Pharmaceuticals, Inc. Announces Timing for First Quarter 2010 Financial Results, Webcast and Conference Call
Download PDF CAMBRIDGE, Mass., Apr 22, 2010 (BUSINESS WIRE) –AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that financial results for the company’s first quarter ended March 31, 2010 will be released before the market opens on Thursday, April 29, 2010. The management team of
AVEO Pharmaceuticals’ Selective Anti-Notch1 Monoclonal Antibody Exhibits Potent Notch1 Inhibitory Activity
Download PDF Data Presented at AACR 101st Annual Meeting 2010; Confirm Potential Utility of AVEO’s Antibody Pipeline CAMBRIDGE, Mass., Apr 21, 2010 (BUSINESS WIRE) –AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced preclinical data which demonstrate that its Notch1-specific monoclonal antibody is a highly potent inhibitor
AVEO Pharmaceuticals Receives Milestone Payment from Biogen Idec under Licensing Agreement for ErbB3 Antibody Program
Download PDF Milestone Achieved Through Selection of First ErbB3 Antibody Development Candidate CAMBRIDGE, Mass., Apr 14, 2010 (BUSINESS WIRE) –AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced it has received a $5 million milestone payment from Biogen Idec International GmbH, a subsidiary of Biogen Idec, Inc.
Data from AVEO Pharmaceuticals’ Translational Research Platform and Novel Antibody Pipeline to be Presented at AACR 101st Annual Meeting 2010
Download PDF CAMBRIDGE, Mass., Apr 13, 2010 (BUSINESS WIRE) –AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that preclinical data from its translational research platform and antibody pipeline will be presented during six poster sessions at the American Association for Cancer Research (AACR) 101st Annual Meeting